NASDAQ:AYTUAytu Bioscience Stock Price, Forecast & News

Aytu Bioscience's stock was trading at $1.35 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, AYTU stock has decreased by 5.6% and is now trading at $1.2750.
View which stocks have been most impacted by Coronavirus.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aytu Bioscience in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Aytu Bioscience.

Aytu Bioscience is scheduled to release its next quarterly earnings announcement on Thursday, September 24th 2020.
View our earnings forecast for Aytu Bioscience.

Aytu Bioscience Inc (NASDAQ:AYTU) announced its quarterly earnings data on Thursday, May, 14th. The company reported ($0.15) EPS for the quarter, topping analysts' consensus estimates of ($0.22) by $0.07. The firm earned $8.16 million during the quarter, compared to analysts' expectations of $7 million. Aytu Bioscience had a negative net margin of 172.62% and a negative return on equity of 107.69%.
View Aytu Bioscience's earnings history.

Aytu Bioscience's stock reverse split on Tuesday, August 29th 2017. The 1-20 reverse split was announced on Friday, August 25th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Monday, August 28th 2017. An investor that had 100 shares of Aytu Bioscience stock prior to the reverse split would have 5 shares after the split.

2 equities research analysts have issued 1-year price targets for Aytu Bioscience's stock. Their forecasts range from $3.00 to $5.00. On average, they expect Aytu Bioscience's stock price to reach $4.25 in the next twelve months. This suggests a possible upside of 233.3% from the stock's current price.
View analysts' price targets for Aytu Bioscience.

Media headlines about AYTU stock have trended somewhat positive this week, InfoTrie Sentiment reports. The research firm identifies positive and negative media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Aytu Bioscience earned a media sentiment score of 1.0 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near term.
View the latest news about Aytu Bioscience.

Aytu Bioscience saw a increase in short interest in the month of March. As of March 13th, there was short interest totaling 3,036,400 shares, an increase of 303.0% from the February 27th total of 753,500 shares. Based on an average daily volume of 38,521,000 shares, the days-to-cover ratio is currently 0.1 days.
View Aytu Bioscience's Short Interest.

Some companies that are related to Aytu Bioscience include Tricida (TCDA), Vanda Pharmaceuticals (VNDA), Aprea Therapeutics (APRE), Emisphere Technologies (EMIS), Flexion Therapeutics (FLXN), Eagle Pharmaceuticals (EGRX), G1 Therapeutics (GTHX), Basilea Pharmaceutica (BPMUF), Applied Therapeutics (APLT), Cue Biopharma (CUE), Corbus Pharmaceuticals (CRBP), Syndax Pharmaceuticals (SNDX), Radius Health (RDUS), Viking Therapeutics (VKTX) and Syros Pharmaceuticals (SYRS).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Aytu Bioscience investors own include Sorrento Therapeutics (SRNE), Vaxart (VXRT), Chesapeake Energy (CHKAQ), Chesapeake Energy (CHKAQ), Heat Biologics (HTBX), Inovio Pharmaceuticals (INO), ADMA Biologics (ADMA), BioNano Genomics (BNGO), VBI Vaccines (VBIV) and Matinas BioPharma (MTNB).

Aytu Bioscience trades on the NASDAQ under the ticker symbol "AYTU."

Aytu Bioscience's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Virtu Financial LLC (0.08%), Commonwealth Equity Services LLC (0.07%), New York State Common Retirement Fund (0.05%), UBS Group AG (0.02%), Searle & CO. (0.02%) and HighTower Advisors LLC (0.02%). Company insiders that own Aytu Bioscience stock include Armistice Capital Master Fund, David A Green and Joshua R Disbrow.
View institutional ownership trends for Aytu Bioscience.

AYTU stock was sold by a variety of institutional investors in the last quarter, including Searle & CO..
View insider buying and selling activity for Aytu Bioscience.

AYTU stock was bought by a variety of institutional investors in the last quarter, including Virtu Financial LLC, New York State Common Retirement Fund, Commonwealth Equity Services LLC, Creative Planning, Global Strategic Investment Solutions LLC, UBS Group AG, and HighTower Advisors LLC. Company insiders that have bought Aytu Bioscience stock in the last two years include Armistice Capital Master Fund, and Joshua R Disbrow.
View insider buying and selling activity for Aytu Bioscience.

Shares of AYTU can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of AYTU stock can currently be purchased for approximately $1.28.

Aytu Bioscience has a market capitalization of $153.78 million and generates $7.32 million in revenue each year. The company earns $-27,130,000.00 in net income (profit) each year or ($3.48) on an earnings per share basis. Aytu Bioscience employs 52 workers across the globe.

The official website for Aytu Bioscience is aytubio.com.

Aytu Bioscience's mailing address is 373 INVERNESS PARKWAY SUITE 206, ENGLEWOOD CO, 80112. The company can be reached via phone at 720-437-6580 or via email at [email protected]